^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
Published date:
12/02/2023
Excerpt:
A total of 82 and 85 tumor samples out of 100 pts were available for PD-L1 assessment using 22C3 and SP142 assays, respectively. Most pts had PDL1-negative tumors (87.8% with 22C3 [CPS < 10]...1L ATZ + BVZ + PTX demonstrated encouraging anti-tumor activity in aTNBC pts, most of them presenting with PD-L1-negative tumors.
Secondary therapy:
paclitaxel
Trial ID:
